BACKGROUND: We evaluated the incidence and spectrum of pathogenic and likely pathogenic variants of cancer susceptibility genes in BRCA1/2 mutation-negative Korean patients with a high risk for hereditary breast cancer using a comprehensive multigene panel that included 35 cancer susceptibility genes. METHODS: Samples from 120 patients who were negative for BRCA1/2 mutations, but had been diagnosed with breast cancer that was likely hereditary, were prospectively evaluated for the prevalence of high-penetrance and moderate-penetrance germline mutations. RESULTS: Nine patients (7.5%) had at least one pathogenic or likely pathogenic variant. Ten variants were identified in these patients: TP53 in two patients, PALB2 in three patients, BARD1 i...
Introduction About 5%–10% of the hereditary breast and/or ovarian cancer (BC/BOC) is associated wit...
Purpose Unclassified variants (UVs) of BRCA1 and BRCA2 genes are not defined as pathogenic for b...
Background: In kindreds carrying path_BRCA1/2 variants, some women in these families will develop ca...
Abstract Background We evaluated the incidence and spectrum of pathogenic and likely pathogenic vari...
Genetic testing for BRCA1 and BRCA2 is crucial in diagnosing hereditary breast and ovarian cancer sy...
"BRCAX" refers breast cancers occurring in women with a family history predictive of being a BRCA1/2...
Purpose: The aim of the study was to evaluate the clinical implication of multigene panel testing of...
Today we are increasingly interested in finding out the hereditary variants of moderate risk from a ...
Objectives: The aim was to point out the importance of the diagnosis rate of breast cancer (BC) by a...
PURPOSE: Comparison of variant frequencies in the general population has become an essential part of...
Background: Hereditary breast cancer (BC), ovarian cancer (OC), and pancreatic cancer (PC) are the m...
BackgroundDue to historically low uptake of genetic testing, the mutational spectrum of Asians with ...
We have surveyed 191 prospectively sampled familial cancer patients with no previously detected path...
In this study, we performed a comprehensive analysis of BRCA1/2 variants and associated cancer risk ...
Background: Germline genetic testing with hereditary cancer gene panels can identify women at increa...
Introduction About 5%–10% of the hereditary breast and/or ovarian cancer (BC/BOC) is associated wit...
Purpose Unclassified variants (UVs) of BRCA1 and BRCA2 genes are not defined as pathogenic for b...
Background: In kindreds carrying path_BRCA1/2 variants, some women in these families will develop ca...
Abstract Background We evaluated the incidence and spectrum of pathogenic and likely pathogenic vari...
Genetic testing for BRCA1 and BRCA2 is crucial in diagnosing hereditary breast and ovarian cancer sy...
"BRCAX" refers breast cancers occurring in women with a family history predictive of being a BRCA1/2...
Purpose: The aim of the study was to evaluate the clinical implication of multigene panel testing of...
Today we are increasingly interested in finding out the hereditary variants of moderate risk from a ...
Objectives: The aim was to point out the importance of the diagnosis rate of breast cancer (BC) by a...
PURPOSE: Comparison of variant frequencies in the general population has become an essential part of...
Background: Hereditary breast cancer (BC), ovarian cancer (OC), and pancreatic cancer (PC) are the m...
BackgroundDue to historically low uptake of genetic testing, the mutational spectrum of Asians with ...
We have surveyed 191 prospectively sampled familial cancer patients with no previously detected path...
In this study, we performed a comprehensive analysis of BRCA1/2 variants and associated cancer risk ...
Background: Germline genetic testing with hereditary cancer gene panels can identify women at increa...
Introduction About 5%–10% of the hereditary breast and/or ovarian cancer (BC/BOC) is associated wit...
Purpose Unclassified variants (UVs) of BRCA1 and BRCA2 genes are not defined as pathogenic for b...
Background: In kindreds carrying path_BRCA1/2 variants, some women in these families will develop ca...